Blood Testing Market: Guardant Health IP Court Appeal

Guardant Health Appeals IP Ruling, Shields Key Blood Tests From Royalty Impact 

PALO ALTO, California August 24, 2026 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced it will appeal the final judgment issued by the U.S. District Court for the District of Delaware in an intellectual property dispute brought by TwinStrand Biosciences, Inc. and the University of Washington, a development with significant implications for the broader Blood Testing Market. The execution of the final judgment and collection of potential royalties have been stayed pending the outcome of the appeal. 

The legal action centers on patent infringement claims related to Guardant's liquid biopsy technology. Guardant Health stated it "strongly disagrees" with the court's decision and expressed confidence in its ability to prevail on appeal. Critically, the company confirmed that its current commercial products Guardant Reveal and Shield are expressly excluded from the scope of the final order, which was defined to cover only products that existed at the time of the 2023 trial, many of which have since been discontinued or significantly upgraded. 

The global Blood Testing Market was valued at USD 91.31 billion in 2023 and is projected to reach USD 147.61 billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030, according to Next Move Strategy Consulting. Intellectual property disputes of this nature, particularly those involving liquid biopsy and next-generation sequencing platforms, are increasingly shaping competitive dynamics within this high-growth sector. 

In addition to the appeal, Guardant Health disclosed that it has validated design improvements to its Guardant360 platform and related services that would effectively exclude the impact of any potential ongoing royalties arising from the court's decision. The company is simultaneously pursuing separate appeals before the U.S. Court of Appeals for the Federal Circuit, and noted that both TwinStrand patents have been preliminarily invalidated in ongoing challenges before the U.S. Patent and Trademark Office. 

Key Highlights: 

• Products Protected: Current versions of Guardant Reveal and Shield blood tests are expressly excluded from the scope of the District Court's final order and any associated royalty obligations. 

• Design Improvements Validated: Guardant Health has confirmed validated design improvements to Guardant360 that would negate the financial impact of potential ongoing royalties. 

• Royalties Stayed: Execution of the final judgment and collection of potential royalties are stayed pending the appeal, limiting near-term financial exposure. 

• Patent Challenges Active: Both TwinStrand patents at the center of the dispute have been preliminarily invalidated in proceedings before the U.S. Patent and Trademark Office, strengthening Guardant's legal position. 

Analyst Insight: 

According to analysts at Next Move Strategy Consulting, intellectual property litigation in the liquid biopsy and blood-based diagnostics segment is becoming a defining competitive variable as the market scales toward USD 147.61 billion by 2030. NMSC analysts note that the outcome of Guardant Health's appeal could set a precedent for how next-generation sequencing-based blood testing patents are adjudicated, with downstream implications for licensing structures, R&D investment strategies, and market entry barriers across the precision oncology diagnostics landscape. The confirmation that flagship commercial products remain unaffected by the current order is likely to preserve near-term revenue stability for the company. 

Industry Outlook: 

The Guardant Health IP appeal underscores the intensifying legal and regulatory scrutiny surrounding proprietary blood testing technologies as the sector matures. With the global blood testing market on a sustained growth trajectory driven by rising disease prevalence, expanding clinical applications, and technological innovation in nucleic acid testing and next-generation sequencing, the resolution of foundational patent disputes will be closely monitored by investors, clinical partners, and competing diagnostics firms alike. The stay on royalty collection provides Guardant Health operational continuity while the appellate process unfolds, and the company's proactive design improvements signal a strategic commitment to insulating its commercial portfolio from litigation risk. 

Source: Guardant Health Investor Relations Business Wire

For More Information: Download FREE Sample on Blood Testing Market Report

By: Sanyukta Deb